Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine. - Wikidata - wikimedia - TriplyDB

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

http://www.wikidata.org/entity/Q37888461

about

Special Technologies for Ex Vivo Analysis of Cancer Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets Unraveling novel TF-miRNA regulatory crosstalk in metastasis of Soft Tissue Sarcoma Rapid screening of novel agents for combination therapy in sarcomas The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: a hybrid model study.Feasibility and clinical value of CT-guided (125)I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure.Sarcoma-The standard-bearer in cancer discovery.

P2860

Q28087644-E105E15A-0F14-4B53-8D00-D54B4EBAC831 Q34504946-50757DEB-DB47-4698-832F-B2F1B55A012E Q35616920-65AF227F-4A0D-4E8E-9E23-157F2D462870 Q37298877-F7A64CEA-DF0D-4347-BB75-C01E1F70757E Q41047795-CF1B8DAD-13F9-4EF6-8224-91740952F477 Q49691413-831A95C3-1386-4A6C-AF45-A3AF318C0BEE Q55379483-6903560C-C696-4D01-B680-B9CC344DCC6B

P2860

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

http://www.wikidata.org/entity/Q37888461

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

@en

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

@nl

type

label

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

@en

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

@nl

prefLabel

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

@en

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

@nl

P1433

Q37888461-16F86671-6343-4DD9-B3AF-747B8D060293

P1476

Q37888461-903D7FA3-3D2C-484B-9BA2-929E17746B57

P2093

Q37888461-3700F00B-1FB8-419C-8AB4-B23220589C60

Q37888461-F101A40D-B17C-437C-BB6C-A49D97B2B3BF

P2860

Q37888461-050AE5FE-6051-46EC-BB63-3A0FD8AC88A3

Q37888461-1167937C-033A-49C8-8298-D8B1379C763F

Q37888461-14380281-7550-4709-B7CD-279FFF37EE79

Q37888461-147E6D86-C70D-40DE-A0E0-20249351B5FC

Q37888461-20430DC9-B9F9-493A-8CCC-32362F77A8A3

Q37888461-23B5FA31-675C-41B8-BC5A-3A7E1913B8D2

Q37888461-255FBBA4-FB25-4D0B-90D2-410EDBB076A8

Q37888461-29E8E80E-9EB0-49C5-82CE-91C54C4A26BB

Q37888461-2B2A40FA-948D-4364-80CC-3F478B996707

Q37888461-2BF7874D-44DE-41B5-9AB7-46D691464B7C

P304

Q37888461-1CA265E6-5B66-4392-BD08-6AD965943EDE

P31

Q37888461-E8AAA965-9518-49E0-A0EF-9B78076C1B11

P356

Q37888461-A8FE2AB6-DFE9-41E7-8EA7-481161887D35

P433

Q37888461-808E0F46-1726-4E57-AF24-CA0ECB02D217

P478

Q37888461-C260BCCB-0A7C-474A-A86C-8144420B1366

P577

Q37888461-EBF3FBD6-C24F-46D8-A618-B496188347F3

P698

Q37888461-C2491894-7A15-4636-9377-1AACB4FD4650

P921

Q37888461-27FFFC72-5981-46B1-994F-C29397ABA797

P356

107327481101800306

P1433

P1476

Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.

@en

P2093

Damon Reed

http://www.w3.org/2001/XMLSchema#string

Soner Altiok

http://www.w3.org/2001/XMLSchema#string

P2860

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma

Feasibility of chemosensitivity testing in soft tissue sarcomas

Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

Differential sensitivity of liposarcoma subtypes to chemotherapy.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

P304

188-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/107327481101800306

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21666581

http://www.w3.org/2001/XMLSchema#string

P921